The Medical Letter on Drugs and Therapeutics
Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a third oral dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, was recently approved by the FDA for treatment of type 2 diabetes, either alone or in combination with metformin, a sulfonylurea or pioglitazone.

DRUGS FOR DIABETES — Metformin (Glucophage, and others) is generally preferred as the first-line oral hypoglycemic agent. A sulfonylurea, such as glimepiride (Amaryl, and others), is less likely than metformin to be effective as monotherapy and may cause weight gain and hypoglycemia. The thiazolidinedione pioglitazone (Actos) is effective for glycemic control, but can also cause weight gain, increases the risk of heart failure and was recently removed from the market in France and Germany because of concerns about an association with bladder cancer. If the desired glycated hemoglobin (A1C) goal is not achieved with metformin, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes
Article code: 1367a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian